This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio Management

Management criteria checks 2/4

Key information

Thomas Cannell

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage	11.3%
CEO tenure	4.6yrs
CEO ownership	0.05%
Management average tenure	3.6yrs
Board average tenure	3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Thomas Cannell's remuneration changed compared to Sesen Bio's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	-US$20m
Sep 30 2022	n/a	n/a	-US$3m
Jun 30 2022	n/a	n/a	US$48m
Mar 31 2022	n/a	n/a	US$54m
Dec 31 2021	US$5m	US$558k	-US$336k
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$118m
Mar 31 2021	n/a	n/a	-US$119m
Dec 31 2020	US$2m	US$533k	-US$23m
Sep 30 2020	n/a	n/a	-US$41m
Jun 30 2020	n/a	n/a	-US$32m
Mar 31 2020	n/a	n/a	-US$60m
Dec 31 2019	US$1m	US$520k	-US$107m
Sep 30 2019	n/a	n/a	-US$81m
Jun 30 2019	n/a	n/a	-US$82m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$2m	US$198k	-US$34m

Compensation vs Market: Thomas's total compensation ($USD4.92M) is above average for companies of similar size in the German market ($USD2.39M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

CEO

Thomas Cannell (60 yo)

4.6yrs

Tenure

US$4,921,698

Compensation

Dr. Thomas R. Cannell, DVM, has been President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Cannell	President	4.6yrs	US$4.92m	0.048% $ 1.2m
Monica Forbes	CFO & Treasurer	3.6yrs	US$1.87m	0.036% $ 878.2k
Glen MacDonald	Chief Technology Officer	6.1yrs	US$1.27m	0.025% $ 611.3k
Gregory L. Verdine	Co-Founder	no data	no data	no data
Elly Ryu	Corporate Controller & Principal Accounting Officer	1.9yrs	no data	0.050% $ 1.2m
Erin Clark	Vice President of Corporate Strategy & Investor Relations	no data	no data	no data
Mark Sullivan	General Counsel	3.6yrs	US$1.15m	0.022% $ 536.8k
Steve Barbera	Vice President of Market Access	1.8yrs	no data	no data
David Brooks	Senior Vice President of Clinical Development	5.8yrs	no data	no data
Dennis Kim	Chief Medical Officer	4.3yrs	US$709.28k	no data
Kirstin Anderson	Senior Director of Finance	1.9yrs	no data	no data
Minori Rosales	Chief Development Officer	1.2yrs	no data	no data

3.6yrs

Average Tenure

53yo

Average Age

Experienced Management: PCBK's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Cannell	President	4.6yrs	US$4.92m	0.048% $ 1.2m
Neal Shore	Member of Medical Advisory Board	no data	no data	no data
Jay Duker	Independent Chairman of the Board	8.2yrs	US$251.28k	0% $ 0
Michael Jewett	Independent Director	1.7yrs	US$469.77k	0% $ 0
Carrie Bourdow	Independent Director	3.1yrs	US$215.91k	0% $ 0
Jason Keyes	Independent Director	3.1yrs	US$219.01k	0% $ 0
Wassim Kassouf	Member of Medical Advisory Board	no data	no data	no data
Rian Dickstein	Member of Medical Advisory Board	no data	no data	no data
Thomas Keane	Member of Medical Advisory Board	no data	no data	no data
Donald Lamm	Member of Medical Advisory Board	no data	no data	no data
Alon Weizer	Member of Medical Advisory Board	no data	no data	no data
Michael O'Donnell	Member of Medical Advisory Board	no data	no data	no data

3.1yrs

Average Tenure

59.5yo

Average Age

Experienced Board: PCBK's board of directors are considered experienced (3.1 years average tenure).

This company is no longer active

Sesen Bio Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently bought €159k worth of stock

Insider recently bought €135k worth of stock

Insider recently bought €797k worth of stock

Insider recently bought €1.2m worth of stock

High number of new directors

Recent updates

Full year 2022 earnings released: US$0.099 loss per share (vs US$0.002 loss in FY 2021)

Sesen Bio, Inc. Announces Special Cash Dividend

Sesen Bio Receives NASDAQ Delisting Notice

Insider recently bought €159k worth of stock

Bradley L Radoff Issues a Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support

Bradley L Radoff Sends a Letter to Sesen Bio Inc

Insider recently bought €135k worth of stock

Bradley L. Radoff and Michael Torok Issue Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote Against Proposed Carisma Merger

Bradley L. Radoff Reiterates Intent to Vote Against Sesen Bio’s Merger with Carisma Therapeutics

Sesen Bio and Carisma Therapeutics Announces Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger

Insider recently bought €797k worth of stock

Insider recently bought €1.2m worth of stock

Third quarter 2022 earnings released: EPS: US$0.10 (vs US$0.36 in 3Q 2021)

CARISMA Therapeutics Inc. entered into a definitive merger agreement to acquire Sesen Bio, Inc. (NasdaqCM:SESN) for approximately $190 million in a reverse merger transaction.

CARISMA Therapeutics Inc. entered into a definitive merger agreement to acquire Sesen Bio, Inc. (NasdaqCM:SESN) for approximately $190 million in a reverse merger transaction.

Sesen Bio, Inc. Announces the U.S. District Court for the District of Massachusetts Issue an Order Granting Preliminary Approval of the Proposed Settlement

First half 2022 earnings released

Sesen Bio, Inc. Announces That It Has Made the Strategic Decision to Voluntarily Pause Further Development in the US of Its Lead Asset, Vicineum

Sesen Bio, Inc. Updates on Meeting with U.S. Food and Drug Administration

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum

Independent Director Jane Pritchett Henderson has left the company

Hagens Berman Notifies Sesen Bio, Inc. Investors of Lead Plaintiff Opportunity in Securities Class Action

Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit Against Sesen Bio, Inc and Certain of its Officers

The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Sesen Bio, Inc

Forecast breakeven moved forward to 2022

High number of new directors

Sesen Bio, Inc. Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US

Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™

Forecast breakeven moved forward to 2022

Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™

Sesen Bio, Inc. Announces U.S. Food and Drug Administration has Accepted for Filing the Biologic License Application for VicineumTM

New 90-day high: €2.50

Sesen Bio Announces Successful Application Orientation Meeting (AOM) with the FDA for Vicineum™

New 90-day high: €1.60

Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum Accepted for Review by the National Medical Products Administration in China

Sesen Bio Submits Completes Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review

Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum Based on the Final Evidence Report Issued by Institute for Clinical and Economic Review

Sesen Bio Enters into Commercial Manufacturing and Supply Framework Agreement with Qilu Pharmaceutical Co., Ltd

New 90-day high: €1.25

Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa

Sesen Bio, Inc. Receives $10.0 Million in Net Proceeds Associated with the $12 Million Upfront Payment Due Under Its Exclusive License Agreement

New 90-day high: €1.05

New 90-day high - €0.88

Sesen Bio, Inc.(NasdaqGM:SESN) dropped from Russell Microcap Growth Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age